Ángel Lucio

Ángel Lucio serves as the CEO of Tetraneuron, a biotech company focused on developing a groundbreaking gene therapy for Alzheimer's disease. With a keen understanding of the challenges posed by the high costs and complexities of gene therapies, Lucio is dedicated to navigating the path from research to clinical application. He aims to ensure that their innovative treatment can reach patients suffering from moderate to severe Alzheimer's, ultimately striving to provide hope for those affected by this devastating condition.